Clinical Trials

A Phase 1/2 Study of Selinexor in Combination with Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma


Study ID
XPORT-GBM-029

NCT Number
NCT04421378 (Click on the NCT number for more information about the trial)

Research Study Number
2020-0284

Principle Investigator
Dr. Goldlust, Samuel

Phase
I/II

Sponsor
Karyopharm Therapeutics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now